ATE221662T1 - Hemmung von tau-tau-verknüpfung - Google Patents

Hemmung von tau-tau-verknüpfung

Info

Publication number
ATE221662T1
ATE221662T1 AT96910015T AT96910015T ATE221662T1 AT E221662 T1 ATE221662 T1 AT E221662T1 AT 96910015 T AT96910015 T AT 96910015T AT 96910015 T AT96910015 T AT 96910015T AT E221662 T1 ATE221662 T1 AT E221662T1
Authority
AT
Austria
Prior art keywords
tau
disease
present
pathological
inhibition
Prior art date
Application number
AT96910015T
Other languages
English (en)
Inventor
Claude Michel Wischik
Patricia Carol Edwards
Charles Robert Harrington
Martin Roth
Aaron Klug
Original Assignee
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10771951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE221662(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Aberdeen filed Critical Univ Aberdeen
Application granted granted Critical
Publication of ATE221662T1 publication Critical patent/ATE221662T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
AT96910015T 1995-03-27 1996-03-25 Hemmung von tau-tau-verknüpfung ATE221662T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9506197.4A GB9506197D0 (en) 1995-03-27 1995-03-27 Inhibition of tau-tau association.
PCT/EP1996/001307 WO1996030766A1 (en) 1995-03-27 1996-03-25 Inhibition of tau-tau-association

Publications (1)

Publication Number Publication Date
ATE221662T1 true ATE221662T1 (de) 2002-08-15

Family

ID=10771951

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00121739T ATE470860T1 (de) 1995-03-27 1996-03-25 Hemmung von tau-tau-verknüpfung
AT96910015T ATE221662T1 (de) 1995-03-27 1996-03-25 Hemmung von tau-tau-verknüpfung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00121739T ATE470860T1 (de) 1995-03-27 1996-03-25 Hemmung von tau-tau-verknüpfung

Country Status (17)

Country Link
US (5) US6376205B1 (de)
EP (2) EP1067386B1 (de)
JP (1) JP3612078B2 (de)
CN (3) CN100406892C (de)
AT (2) ATE470860T1 (de)
AU (1) AU5334496A (de)
BR (1) BR9607846B1 (de)
CA (2) CA2215397C (de)
DE (2) DE69622701T2 (de)
DK (2) DK1067386T3 (de)
ES (2) ES2180753T3 (de)
GB (1) GB9506197D0 (de)
HK (1) HK1068950A1 (de)
MX (1) MX9706902A (de)
PT (2) PT1067386E (de)
TR (1) TR199701039T1 (de)
WO (1) WO1996030766A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US7252950B1 (en) 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
CA2300869A1 (en) * 1997-09-04 1999-03-11 Ron Vale Assays for detecting modulators of cytoskeletal function
CN1100787C (zh) * 1998-05-08 2003-02-05 北京大学 新型血吸虫疫苗肽
ATE326700T1 (de) * 1999-09-09 2006-06-15 Max Planck Gesellschaft SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
CA2357450A1 (en) * 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AU2007200212B2 (en) * 2001-01-15 2010-08-26 Wista Laboratories Ltd. Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0113121D0 (en) 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
GB0117326D0 (en) * 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US20050079526A1 (en) * 2002-02-20 2005-04-14 Affinium Pharmaceuticals, Inc. Methods and apparatuses for characterizing refolding and aggregation of biological molecules
WO2003078448A1 (en) * 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
ES2311734T3 (es) * 2002-07-12 2009-02-16 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Proteinas tau truncadas.
US7172875B2 (en) * 2003-02-18 2007-02-06 The Ohio State University Research Foundation Identifying inhibitors of intracellular protein fibrillization
US20070031336A1 (en) * 2003-08-18 2007-02-08 Yves Auberson 3H-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof
WO2005080986A1 (en) * 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
TR201910292T4 (tr) 2004-09-23 2019-08-21 Wista Lab Ltd Metiltiyoninyum klorür (mtc) içeren diaminofenotiazinyum bileşiklerinin kimyasal sentezi ve saflaştırılması için yöntemler.
US8221804B2 (en) * 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US20060188866A1 (en) * 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
CN103735554B (zh) 2006-03-29 2018-03-20 维斯塔实验室有限公司 蛋白聚集抑制剂
AU2013200732B2 (en) * 2006-03-29 2015-04-09 Wista Laboratories Ltd. 3,7-diamino-10H-phenothiazine salts and their use
PL2853293T3 (pl) 2006-03-29 2018-05-30 Wista Laboratories Ltd. Związki tioniny i ich zastosowanie
CN104606199B (zh) * 2006-03-29 2022-09-13 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
LT2457905T (lt) 2006-07-11 2016-11-10 Wista Laboratories Ltd. Diaminofenotiazino junginių sintezės ir (arba) gryninimo metodai
US20110263696A1 (en) * 2007-03-30 2011-10-27 Graves Donald J Proanthocyanidins from cinnamon and its water soluble extract inhibit tau aggregation
CN101820884B (zh) * 2007-06-19 2013-08-28 维斯塔实验室有限公司 用于治疗轻度认知缺损的吩噻嗪化合物
DK2205245T3 (en) 2007-10-03 2015-09-28 Wista Lab Ltd Therapeutic use of diaminophenothiaziner
EP2090166A1 (de) * 2008-02-14 2009-08-19 Bayer CropScience AG Flüssige herbizide Zubereitungen
US8715643B2 (en) 2008-04-09 2014-05-06 Tokyo Metropolitan Institute Of Medical Science TDP-43-storing cell model
ES2973458T3 (es) * 2008-12-10 2024-06-20 Wista Lab Ltd Sales de xantilio 3,6-disustituidas como medicamentos para tratar taupatías
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
PT2430007E (pt) 2009-05-12 2014-04-14 Wista Lab Ltd Métodos de síntese química de compostos de diaminofenotiazínio que envolvem a utilização de oxidantes de persulfato
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
SI3378856T1 (sl) 2009-09-24 2021-03-31 Wista Laboratories Ltd. Kristalinični metiltioninijevi klorid hidrati
WO2011045166A1 (en) * 2009-09-24 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
WO2011056222A1 (en) * 2009-11-05 2011-05-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein aggregation
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US8796448B1 (en) * 2010-12-09 2014-08-05 Prosetta Antiviral Inc. Compounds, compositions, and methods for treating Alzheimer's disease
SG190406A1 (en) 2010-11-30 2013-06-28 Wista Lab Ltd Formulations comprising methylthioninium chloride
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
EP2670434B1 (de) * 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Behandlung von tauopathien
WO2012107706A1 (en) 2011-02-11 2012-08-16 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
US8349376B1 (en) * 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
WO2012162179A1 (en) * 2011-05-20 2012-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
US8980884B2 (en) 2011-06-01 2015-03-17 Wisconsin Alumni Research Foundation Methods for treating Alzheimer's disease
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
SG10201912955PA (en) * 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
WO2013151762A1 (en) 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
JP6568514B2 (ja) 2013-03-15 2019-08-28 エーシー イミューン エス．エー． 抗タウ抗体及び使用方法
GB201317702D0 (en) 2013-10-07 2013-11-20 Wista Lab Ltd Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
US10765755B1 (en) 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
JP6370674B2 (ja) * 2014-10-22 2018-08-08 国立研究開発法人国立長寿医療研究センター タウオパチー治療薬およびそのスクリーニング方法
US10799523B2 (en) * 2015-02-04 2020-10-13 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
KR101722930B1 (ko) * 2015-06-19 2017-04-04 한국과학기술연구원 전이성 타우 단백질 및 이의 제조 방법
GB201512678D0 (en) 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
SI3487505T1 (sl) 2016-07-25 2023-10-30 Wista Laboratories Ltd., Dajanje in odmerek diaminofenotiazinov
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
AU2018317807A1 (en) * 2017-08-16 2020-02-06 Roxiant ApS VTFT isoform of a BPIFB4 protein for use in neuronal diseases and injuries
EP4385512A1 (de) 2018-07-26 2024-06-19 WisTa Laboratories Ltd. Optimierte dosierung von diaminophenothiazinen in populationen
EP3946605A1 (de) 2019-04-05 2022-02-09 Tauc3 Biologics Limited Anti-tauc3-antikörper und verwendungen davon
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
GB202010620D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd System
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
GB202213796D0 (en) 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US391675A (en) * 1888-10-23 Rack for exhibiting hose or other goods
BE569430A (de) * 1957-07-17
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US5571666A (en) * 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
JPH0833127B2 (ja) * 1990-05-01 1996-03-29 株式会社ユニシアジェックス 内燃機関の空燃比制御装置
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
AU653629B2 (en) 1991-07-10 1994-10-06 Minnesota Mining And Manufacturing Company Fluorochemical water- and oil- repellent treating compositions
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
WO1993003177A1 (en) * 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
DE69233767D1 (de) 1991-12-06 2009-09-17 Max Planck Gesellschaft Verwendung von Protein-Kinasen zur Diagnose und Behandlung der Alzheimer-Krankheit
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
CA2196529A1 (en) 1994-08-08 1996-02-22 Peter Davies Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US6953675B2 (en) * 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
AU2001229619A1 (en) 2000-01-21 2001-07-31 Pharmacia And Upjohn Company Transgenic mouse model of human neurodegenerative disease
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
US7939538B2 (en) 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US7838107B2 (en) 2004-09-14 2010-11-23 Denki Kagaku Kogyo Kabushiki Kaisha Aluminum-silicon carbide composite
TR201910292T4 (tr) 2004-09-23 2019-08-21 Wista Lab Ltd Metiltiyoninyum klorür (mtc) içeren diaminofenotiazinyum bileşiklerinin kimyasal sentezi ve saflaştırılması için yöntemler.

Also Published As

Publication number Publication date
MX9706902A (es) 1997-11-29
CN1935143A (zh) 2007-03-28
ES2180753T3 (es) 2003-02-16
US6376205B1 (en) 2002-04-23
EP1067386B1 (de) 2010-06-09
CA2215397A1 (en) 1996-10-03
CN1179829A (zh) 1998-04-22
US6953794B2 (en) 2005-10-11
US20060014216A1 (en) 2006-01-19
CN1150404C (zh) 2004-05-19
WO1996030766A1 (en) 1996-10-03
BR9607846B1 (pt) 2009-05-05
EP1067386A3 (de) 2004-11-24
CN100406892C (zh) 2008-07-30
JPH11502925A (ja) 1999-03-09
GB9506197D0 (en) 1995-05-17
DE69622701D1 (de) 2002-09-05
EP1067386A2 (de) 2001-01-10
US8278298B2 (en) 2012-10-02
BR9607846A (pt) 1998-07-14
DK0817969T3 (da) 2002-11-25
JP3612078B2 (ja) 2005-01-19
ATE470860T1 (de) 2010-06-15
CA2633573A1 (en) 1996-10-03
US20080207604A1 (en) 2008-08-28
PT817969E (pt) 2002-12-31
ES2346284T3 (es) 2010-10-14
US7534786B2 (en) 2009-05-19
CA2633573C (en) 2010-09-14
DK1067386T3 (da) 2010-10-04
AU5334496A (en) 1996-10-16
US20070191352A1 (en) 2007-08-16
US20020168687A1 (en) 2002-11-14
DE69638197D1 (de) 2010-07-22
TR199701039T1 (xx) 1998-02-21
CA2215397C (en) 2008-12-02
DE69622701T2 (de) 2003-03-06
PT1067386E (pt) 2010-08-31
EP0817969A1 (de) 1998-01-14
HK1068950A1 (en) 2005-05-06
EP0817969B1 (de) 2002-07-31
CN1544945A (zh) 2004-11-10

Similar Documents

Publication Publication Date Title
ATE470860T1 (de) Hemmung von tau-tau-verknüpfung
ATE148469T1 (de) Zyklosporine
CA2117193A1 (en) Vaccine comprising part of constant region of ige for treatment of ige-medicated allergic reactions
NL300272I1 (nl) DNA dat humaan papillomavirus type 18 codeert.
ES2194225T3 (es) Regeneracion morfogenica inducida por peptidos de tejidos perceptores de sentidos.
BG102821A (en) Reprocessed globin products and methods for their preparation
DE69321893D1 (de) Verfahren zum Nachweis von Alzheimer-Krankheit
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
DE69822628D1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner